Patents by Inventor Belinda De Leon

Belinda De Leon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)
    Patent number: 11408004
    Abstract: The present invention relates to antisense oligonucleotide that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: August 9, 2022
    Assignee: CURNA, INC.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
  • SOLID FORMS AND FORMULATIONS COMPRISING A GLUCOCORTICOID RECEPTOR ANTAGONIST AND USES THEREOF
    Publication number: 20210147472
    Abstract: The present invention relates generally to formulations and methods for treating cancer. Provided herein are formulations comprising substituted steroidal derivatives. The subject formulations are useful for the treatment of cancer.
    Type: Application
    Filed: April 11, 2019
    Publication date: May 20, 2021
    Inventors: Valeria R. FANTIN, Qiuping YE, Belinda DE LEON, Daqing SUN, Sunil V. MHASKAR
  • Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
    Patent number: 10793857
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: October 6, 2020
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Belinda De Leon, Carlos Coito, Jane H. Hsiao
  • Antagonat compositions and methods of use
    Patent number: 10000752
    Abstract: Provided herein are compositions, compounds, and methods of modulating gene expression. In certain embodiments described herein is a composition, wherein the composition comprises an antagoNAT. In some embodiments, the antagoNAT is an oligonucleotide comprising modified and unmodified sugar subunits, wherein the antagoNAT hybridizes with a natural antisense transcript. Certain embodiments of the present invention provide a method for modulating gene expression in a cell comprising contacting the cell with an antagoNAT. In some embodiments, the method includes forming a hybrid comprising the antagoNAT and a natural antisense transcript of the gene, wherein the hybrid sterically blocks the normal function of the natural antisense transcript.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: June 19, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Belinda De Leon
  • TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA
    Publication number: 20180002696
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
    Type: Application
    Filed: August 29, 2017
    Publication date: January 4, 2018
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN, Belinda DE LEON, Carlos COITO, Jane H. HSIAO
  • TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA
    Publication number: 20170355990
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
    Type: Application
    Filed: August 29, 2017
    Publication date: December 14, 2017
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN, Belinda DE LEON, Carlos COITO, Jane H. HSIAO
  • Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
    Patent number: 9771579
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: September 26, 2017
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Belinda De Leon, Carlos Coito, Jane H. Hsiao
  • TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)
    Publication number: 20150284724
    Abstract: The present invention relates to antisense oligonucleotide that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Application
    Filed: June 16, 2015
    Publication date: October 8, 2015
    Inventors: Joseph COLLARD, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
  • Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
    Patent number: 9089588
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: July 28, 2015
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
  • ANTAGONAT COMPOSITIONS AND METHODS OF USE
    Publication number: 20130245099
    Abstract: Provided herein are compositions, compounds, and methods of modulating gene expression. In certain embodiments described herein is a composition, wherein the composition comprises an antagoNAT. In some embodiments, the antagoNAT is an oligonucleotide comprising modified and unmodified sugar subunits, wherein the antagoNAT hybridizes with a natural antisense transcript. Certain embodiments of the present invention provide a method for modulating gene expression in a cell comprising contacting the cell with an antagoNAT. In some embodiments, the method includes forming a hybrid comprising the antagoNAT and a natural antisense transcript of the gene, wherein the hybrid sterically blocks the normal function of the natural antisense transcript.
    Type: Application
    Filed: November 17, 2011
    Publication date: September 19, 2013
    Applicant: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Belinda De Leon
  • TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA
    Publication number: 20130096183
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
    Type: Application
    Filed: June 23, 2011
    Publication date: April 18, 2013
    Applicant: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Belinda De Leon, Carlos Coito, Jane H. Hsiao
  • TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)
    Publication number: 20130072421
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Application
    Filed: January 13, 2011
    Publication date: March 21, 2013
    Applicant: CURNA, INC
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
  • TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT1
    Publication number: 20110319317
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.
    Type: Application
    Filed: March 3, 2010
    Publication date: December 29, 2011
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
  • TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRTUIN 1
    Publication number: 20110237649
    Abstract: Oligonucleotide compounds modulate expression and/or function of Sirtuin 1 (SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1 (SIRT1) comprise administering one or more Oligonucleotide compounds designed to inhibit the SIRT1 natural antisense transcript to patients.
    Type: Application
    Filed: December 2, 2009
    Publication date: September 29, 2011
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon